What is a stock summary page? Click here for an overview.
Business Description
Ernexa Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US1140822099
Share Class Description:
ERNA: Ordinary SharesDescription
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.53 | |||||
| Equity-to-Asset | 0.32 | |||||
| Debt-to-Equity | 0.4 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | -83.52 | |||||
| Beneish M-Score | -4.65 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 63.9 | |||||
| 3-Year EPS without NRI Growth Rate | 56.7 | |||||
| 3-Year FCF Growth Rate | 52.3 | |||||
| 3-Year Book Growth Rate | -85 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 34.11 | |||||
| 9-Day RSI | 30.55 | |||||
| 14-Day RSI | 32.73 | |||||
| 3-1 Month Momentum % | -16.89 | |||||
| 6-1 Month Momentum % | -73.28 | |||||
| 12-1 Month Momentum % | -87.57 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.8 | |||||
| Quick Ratio | 0.8 | |||||
| Cash Ratio | 0.59 | |||||
| Days Payable | 7023.97 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -170.3 | |||||
| Shareholder Yield % | -33.5 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 83.51 | |||||
| Operating Margin % | -2963.92 | |||||
| Net Margin % | -7652.75 | |||||
| FCF Margin % | -2784.36 | |||||
| ROA % | -140.71 | |||||
| ROIC % | -58.01 | |||||
| 3-Year ROIIC % | -92.96 | |||||
| ROC (Joel Greenblatt) % | -173.63 | |||||
| ROCE % | -155.47 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.76 | |||||
| PB Ratio | 5.76 | |||||
| EV-to-EBIT | -0.24 | |||||
| EV-to-EBITDA | -0.25 | |||||
| EV-to-Revenue | 15.26 | |||||
| EV-to-FCF | -0.55 | |||||
| Earnings Yield (Greenblatt) % | -416.67 | |||||
| FCF Yield % | -163.24 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ERNA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ernexa Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.582 | ||
| EPS (TTM) ($) | -7.282 | ||
| Beta | 2.17 | ||
| 3-Year Sharpe Ratio | -1.07 | ||
| 3-Year Sortino Ratio | -1.38 | ||
| Volatility % | 89.84 | ||
| 14-Day RSI | 32.73 | ||
| 14-Day ATR ($) | 0.031349 | ||
| 20-Day SMA ($) | 0.23626 | ||
| 12-1 Month Momentum % | -87.57 | ||
| 52-Week Range ($) | 0.1506 - 2.625 | ||
| Shares Outstanding (Mil) | 52.24 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ernexa Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ernexa Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Ernexa Therapeutics Inc Frequently Asked Questions
What is Ernexa Therapeutics Inc(ERNA)'s stock price today?
The current price of ERNA is $0.19. The 52 week high of ERNA is $2.63 and 52 week low is $0.15.
When is next earnings date of Ernexa Therapeutics Inc(ERNA)?
The next earnings date of Ernexa Therapeutics Inc(ERNA) is 2025-05-14 Est..
Does Ernexa Therapeutics Inc(ERNA) pay dividends? If so, how much?
Ernexa Therapeutics Inc(ERNA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers